THE AFRICAN AIDS EXPERIENCE IN CONTRAST WITH THE REST OF THE WORLD NLM AIDSLINE Important note: Information in this article was accurate in 1990. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


THE AFRICAN AIDS EXPERIENCE IN CONTRAST WITH THE REST OF THE WORLD

Infect Dis Ther; 3:43-56 1989. Unique Identifier : AIDSLINE ICDB/90665437
Clumneck N; Carael M; Van de Perre P; Dept. of Internal Medicine, Free Univ. of Brussels, Brussels,; Belgium


Abstract: HIV infection is now endemic in most sub-Saharan African countries. It is thought that 50,000-100,000 people have suffered or died from AIDS in Africa so far. Seroprevalence rates of 1-20% are found in the general population; and 27-88% of certain groups, such as female prostitutes and their clients, may be infected. Several million infected individuals may exist in Africa. Viruses involved in African AIDS, risk factors and cofactors in heterosexual transmission of AIDS, and clinical aspects of HIV infection in Africa are reviewed. HIV in Africa is characterized by heterosexual transmission of the virus in the general population, especially in urban areas. As a consequence of high seroprevalence rates among young women in their childbearing years, HIV infection is affecting children also, and major demographic consequences can be expected in the coming decades. Two forms of Kaposi's sarcoma (KS) exist in Africa. In equatorial Africa, KS is extremely common and accounts for 12.8% of malignant tumors in Zaire, 4.5% in Tanzania, 4.2% in Uganda, and 2.9% in Kenya. A changing pattern of KS was first noted in 1983 in Lusaka, Zambia. The 'new' pattern of KS among African patients (pts) consists of generalized lymphadenopathy and oral, gastrointestinal, or bronchial lesions together with cutaneous infiltrative plaques on the trunk, genital organs, face, and more rarely, limbs. When associated with opportunistic infection, the disease is rapidly fatal. Pts respond about as well to immunotherapy or chemotherapy as American or European homosexual pts. In Africa, as in Western countries, measures aimed at avoiding any further spread of the epidemic among heterosexuals should focus on prevention, detection, and treatment of sexually transmitted infections in general. A community-based approach to control of sexually transmitted infection, focused on prostitutes and other women with multiple sexual partners, pts with sexually transmitted infections, and adolescents, should be implemented together with control of blood donation. Health education programs should be instituted to inform the population about the risk of HIV transmission through contaminated needles, skin-piercing instruments, and sexual contact. Major impediments to such programs in Africa are cost, logistic problems, and misinformation. (60 Refs)
Keywords: Acquired Immunodeficiency Syndrome/COMPLICATIONS/*EPIDEMIOLOGY/ TRANSMISSION Africa/EPIDEMIOLOGY Comparative Study *Cross-Cultural Comparison *Disease Outbreaks Human HIV Infections/COMPLICATIONS/*EPIDEMIOLOGY/TRANSMISSION HIV-1/*ISOLATION & PURIF HIV-2/*ISOLATION & PURIF Opportunistic Infections/COMPLICATIONS/EPIDEMIOLOGY Risk Factors Sarcoma, Kaposi's/EPIDEMIOLOGY Skin Neoplasms/EPIDEMIOLOGY JOURNAL ARTICLEKWDacquiredimmunodeficiencysyndrome/complications/KWDepidemiology/transmissionafrica/epidemiologycomparativestudyKWDcross-culturalcomparisonKWDdiseaseoutbreakshumanhivinfections/complications/KWDepidemiology/transmissionhiv-1/KWDisolation&purifhiv-2/KWDisolation&purifopportunisticinfections/complications/epidemiologyriskfactorssarcoma,kaposi's/epidemiologyskinneoplasms/epidemiologyjournalarticle
901030
M90A0697

Copyright © 1990 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1990. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1990. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .